Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14375228 | 0.86 | HRH3 (0.65) | KCNH2GPR119LMNADRD2CCR2 | |
| SCHEMBL17988147 | 0.85 | KCNH2 (0.52) | KCNH2GPR119LMNADRD2CCR2 | |
| SCHEMBL17967843 | 0.84 | DRD2 (0.51) | KCNH2GPR119LMNADRD2CCR2 | |
| SCHEMBL17988175 | 0.83 | KCNH2 (0.51) | KCNH2GPR119LMNADRD2CCR2 | |
| SCHEMBL17988003 | 0.82 | KCNH2 (0.50) | KCNH2GPR119LMNADRD2CCR2 | |
| SCHEMBL13602644 | 0.82 | MGAT2 (0.59) | KCNH2GPR119LMNADRD2CCR2 | |
| SCHEMBL5744277 | 0.81 | NPC1 (0.59) | ALDH1A1RAB9ADRD2NPC1 | |
| SCHEMBL17987980 | 0.81 | KCNH2 (0.52) | KCNH2GPR119LMNADRD2CCR2 | |
| SCHEMBL21026031 | 0.81 | KCNH2 (0.49) | KCNH2GPR119LMNADRD2CCR2 | |
| SCHEMBL8236801 | 0.80 | HRH3 (0.64) | ALDH1A1CYP2D6LMNAKDM4ECCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | KCNH2 302/4885GPR119 188/4885ALDH1A1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.